Combined Inhibition of SHP2 and CXCR1/2 Promotes Anti-Tumor T Cell Response in NSCLC

By
Justin.choi
-
0
152
The authors found that SHP2 inhibitor treatment depleted alveolar and M2-like macrophages, induced tumor-intrinsic CCL5/CXCL10 secretion and promoted B and T lymphocyte infiltration in Kras- and Egfr-mutant non-small cell lung cancer.
[Cancer Discovery]
Tang, K. H., Li, S., Khodadadi-Jamayran, A., Jen, J., Han, H., Guidry, K., Chen, T., Hao, Y., Fedele, C., Zebala, J. A., Maeda, D. Y., Christensen, J. G., Olson, P., Athanas, A., Loomis, C. A., Tsirigos, A., Wong, K.-K., & Neel, B. G. (2021). Combined Inhibition of SHP2 and CXCR1/2 Promotes Anti-Tumor T Cell Response in NSCLC. Cancer Discovery. https://doi.org/10.1158/2159-8290.CD-21-0369 Cite
Abstract